Analyst Anthony Vendetti of Maxim Group reiterated a Buy rating on Autonomix Medical, Inc., retaining the price target of $5.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Anthony Vendetti has given his Buy rating due to a combination of factors that highlight Autonomix Medical, Inc.’s promising future. The company is making significant progress in its clinical and regulatory strategies, with key programs advancing as planned. Notably, their market expansion study is actively enrolling patients with various visceral cancers and earlier-stage pancreatic cancer, which is expected to broaden their market reach.
Moreover, AMIX’s innovative microchip-based platform technology is on track, with an early feasibility study anticipated to begin soon, followed by a pivotal trial. The potential for managing cancer-related pain effectively without the adverse effects of opioids, along with the company’s strong cash position and no debt, supports the Buy rating. The valuation is further bolstered by a compelling 12-month price target, derived from a detailed financial analysis, and confidence in the management team’s ability to create shareholder value.
AMIX’s price has also changed dramatically for the past six months – from $1.850 to $0.730, which is a -60.54% drop .